文献速递血栓与止血

血友病基因治疗:首先,不造成伤害

Hemophilia gene therapy: first, do no harm.
PubMed 文献 · J Thromb Haemost · 2023-06-21

本文回顾了推动valoctocogene roxaparvovec在欧洲获批治疗血友病A及etranacogene dezaparvovec-drlb在美国和欧洲获批治疗血友病B的数据,并概述了决策过程,建议血友病群体采取措施确保选择接受基因治疗者的安全与最佳结局。

要点

  • 腺相关病毒介导的肝靶向基因治疗为血友病带来希望,但也伴随不确定性。
  • 决策使用基因治疗产品需采用知情、整体和共享决策的方法。
  • 需解决并尽量减少医护人员和血友病患者的偏见。

核心结论

  • 基因治疗引入血友病治疗领域带来巨大希望和相当不确定性,决策需知情、整体和共享决策,并解决偏见。

研究设计与样本

  • 综述,回顾了导致valoctocogene roxaparvovec在欧洲获批治疗血友病A及etranacogene dezaparvovec-drlb在美国和欧洲获批治疗血友病B的数据,并概述决策过程。

临床怎么用

  • 作者建议血友病群体采取措施,确保选择接受基因治疗产品的血友病患者的安全和最佳结局。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The introduction of adeno-associated virus-mediated, liver-directed gene therapy into the hemophilia treatment landscape brings not only great promise but also considerable uncertainty to a community that has a history punctuated by the devastating effects of HIV and hepatitis C virus. These infections were introduced into people with hemophilia through the innovation of factor concentrates in the 1970s and 1980s. Concentrates, heralded as a major advance in treatment at the time, brought devastation and death to the community already challenged by the complications of bleeding into joints, vital organs, and the brain. Over the past 5 decades, considerable advances in hemophilia treatment have improved the survival, quality of life, and participation of people with hemophilia, although challenges remain and health equity with their unaffected peers has not yet been achieved. The decision to take a gene therapy product is one in which an informed, holistic, and shared decision-making approach must be employed. Bias on the part of health care professionals and people with hemophilia must be addressed and minimized. Here, we review data leading to the regulatory authorization of valoctocogene roxaparvovec, an adeno-associated virus 5 gene therapy, in Europe to treat hemophilia A and etranacogene dezaparvovec-drlb in the United States and Europe to treat hemophilia B. We also provide an overview of the decision-making process and recommend steps that should be taken by the hemophilia community to ensure the safety of and optimal outcomes for people with hemophilia who choose to receive a gene therapy product.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Valentino LA, Kaczmarek R, Pierce GF, et al. Hemophilia gene therapy: first, do no harm. J Thromb Haemost. 2023. PMID: 37353081. doi:10.1016/j.jtha.2023.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。